Valuation : Aura Biosciences, Inc.

Market Cap 778M 669M 628M 575M 1.07B 73.52B 1.08B 7.43B 2.89B 37.57B 2.92B 2.86B 121B P/E 2026 *
-4.5x
P/E 2027 * -4.94x
Enterprise Value 778M 669M 628M 575M 1.07B 73.52B 1.08B 7.43B 2.89B 37.57B 2.92B 2.86B 121B EV / Sales 2026 *
-
EV / Sales 2027 * 158x
Free-Float
92.64%
Yield 2026 *
-
Yield 2027 * -
1 day-1.73%
1 week-4.29%
Current month+2.65%
1 month+4.69%
3 months+7.12%
6 months+18.11%
Current year+35.23%
1 week 7
Extreme 7
7.79
1 month 6.96
Extreme 6.96
8.37
Current year 4.73
Extreme 4.73
9.54
1 year 4.73
Extreme 4.73
9.54
3 years 4.34
Extreme 4.345
12.38
5 years 4.34
Extreme 4.345
26.16
10 years 4.34
Extreme 4.345
26.16
Manager TitleAgeSince
Chief Executive Officer 53 2026-04-29
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 61 2023-10-15
Director TitleAgeSince
Director/Board Member 41 2019-03-31
Chairman 61 2020-12-31
Director/Board Member 55 2021-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Controller/Auditor

70,000 0.0675%
9/1/26 Free

Chief Operating Officer

400,000 0.3857%
9/1/26 Free

Chief Technology Officer

175,000 0.1687%
Change 5-day change 1-year change 3-year change Capi.($)
-1.73%-4.29%+16.25%-28.24% 778M
-0.24%-0.99%+3.26%+18.17% 50.14B
+0.78%-4.65%+430.22%+525.91% 44.85B
+2.95%+3.52%+47.12%+22.97% 43.43B
+0.25%-2.63%+7.86%+77.06% 41.14B
+0.43%-3.26%+14.75%+49.08% 32.92B
+1.43%+8.73% - - 17.56B
+0.06%-2.97%+23.31%+123.84% 16.55B
+0.93%+0.88%+19.64%+29.70% 14.65B
+0.54%-1.03%+80.71%+43.59% 13.93B
Average +0.59%-0.99%+71.46%+95.79% 27.59B
Weighted average by Cap. +0.88%-1.13%+93.36%+129.07%

Financials

2026 *2027 *
Net sales - 4.92M 4.24M 3.98M 3.64M 6.79M 466M 6.84M 47.04M 18.32M 238M 18.49M 18.09M 766M
Net income -154M -132M -124M -114M -212M -14.54B -214M -1.47B -572M -7.43B -578M -565M -23.93B -167M -144M -135M -123M -230M -15.79B -232M -1.6B -621M -8.07B -627M -614M -25.99B
Net Debt - -
Logo Aura Biosciences, Inc.
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Employees
113
Date Price Change Volume
26-09-03 US$7.370 -1.73% 875,865
26-09-02 US$7.500 +0.94% 495,494
26-09-01 US$7.430 +3.48% 534,540
26-08-31 US$7.180 -2.97% 602,504
26-08-28 US$7.400 -3.90% 441,402
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.500USD
Average target price
16.60USD
Spread / Average Target
+121.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AURA Stock